Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) is a biotechnology company focused on developing and commercializing next-generation immunotherapies, anchored by its approved product ANKTIVA (nogapendekin alfa inbakicept). This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment and is currently commercializing ANKTIVA for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, in the U.S., EU, UK, and Saudi Arabia.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $44.2 million | $16.5 million |
| Net Loss | $(632.8) million | $(129.7) million |
| Loss Per Share (Basic & Diluted) | $(0.62) | $(0.15) |
| Cash and Cash Equivalents | $205.2 million | $60.7 million |
| Marketable Securities | $175.7 million | $154.5 million |
| Total Liquidity (Cash + Securities) | $380.9 million | $215.2 million |
| Operating Cash Flow | $(75.4) million | $(85.9) million |
| Related-Party Convertible Note (Fair Value) | $678.4 million | $477.1 million |
| Revenue Interest Liability | $404.3 million | $324.6 million |
| Warrant Liabilities | $308.2 million | $84.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 168% year-over-year to $44.2 million, driven by a 168% increase in unit sales volume of ANKTIVA.
- Net Loss Expansion: Net loss widened significantly to $632.8 million from $129.7 million. This increase was primarily driven by non-cash charges related to the change in fair value of warrant liabilities ($295.4 million) and the related-party convertible note ($236.6 million), reflecting increases in the company's stock price.
- Financing Activity: The company raised significant capital in Q1 2026, including $102.1 million from an At-The-Market (ATM) offering, $75.0 million from a Second Amendment to the Revenue Interest Purchase Agreement (RIPA), and $53.5 million from warrant exercises.
- Debt Conversion: Nant Capital converted $25.0 million of principal from the December 2024 Convertible Promissory Note into common stock.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong sales momentum for ANKTIVA and regulatory expansion, including conditional marketing authorization in the EU and approval in Macau. The company expects to continue incurring significant expenses as it commercializes ANKTIVA globally and advances its pipeline. While the company has an accumulated deficit of $4.4 billion, management believes existing cash, marketable securities, and potential additional funding (including support from the Founder) will be sufficient to fund operations for at least the next 12 months.
Going Concern: The filing states that substantial doubt exists regarding the company's ability to continue as a going concern without additional funding or financial support, though this doubt is alleviated by the Founder's intent and ability to provide additional funds.
Key Risks and Contingencies:
- Legal Proceedings: The company is involved in multiple legal matters, including a securities class action regarding an FDA warning letter, shareholder derivative actions, and an arbitration with Shenzhen Beike Biotechnology Co. Ltd. regarding a China license agreement.
- Regulatory: The company received an FDA OPDP warning letter in March 2026 regarding a television advertisement and podcast interview. It is also navigating a "Refuse to File" (RTF) letter history for a supplemental BLA regarding papillary-only disease, though it has refiled the sBLA in February 2026.
- Debt Obligations: The company has significant obligations under the RIPA, including tiered revenue interest payments (5.625% to 12.50% of net sales) and a potential "True-Up Payment" if cumulative payments do not meet a threshold by December 31, 2029.
- Contingent Value Rights (CVRs): Approximately $304 million in CVRs are outstanding from the Altor acquisition, contingent on ANKTIVA sales exceeding $1.0 billion prior to December 31, 2026.
Investor Verification Checklist
- Non-Cash Loss Drivers: Verify the impact of fair value accounting on warrant liabilities and the related-party convertible note, which drove the majority of the reported net loss.
- Liquidity Runway: Assess the sufficiency of the $380.9 million liquidity position against the $480 million principal of the related-party convertible note due in 2027 and ongoing operating cash burn.
- RIPA Terms: Review the specific tiered revenue interest rates and the "True-Up Payment" mechanism under the RIPA to understand future cash flow obligations.
- Legal Exposure: Monitor the status of the securities class action and the SRS/Altor CVR arbitration, which could result in significant financial liability.
- Regulatory Status: Confirm the FDA's response to the March 2026 OPDP warning letter and the acceptance of the refiled sBLA for the papillary-only indication.